Pharmaceutical Industry News 27 October 2025

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly and Company (NYSE: LLY) is catching its breath after one of the wildest runs any pharmaceutical stock has ever seen. On November 29, 2025, the share price is easing off record highs, but the company is still hovering

29 November 2025

Financial News·Investing·Market Analysis·Pharmaceutical Industry·Stock Market

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

On Friday, 28 November 2025, Merck & Co., Inc. (NYSE: MRK) continued to trade near its 52‑week highs as a wave of fresh institutional filings, bullish research notes, and recent oncology approvals kept the spotlight firmly on the pharmaceutical giant.

28 November 2025

Dividends·Financial News·Investing·Pharmaceutical Industry·Stock Market

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Summary Live PFE snapshot (intraday) New today: Pfizer sells debt to fund Metsera Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions

18 November 2025

Mergers & Acquisitions·Pfizer News·Pharmaceutical Industry·Stock Market

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and

17 November 2025

Drug Pricing·Healthcare News·Pharmaceutical Industry

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (NASDAQ: OTLK) shares jumped today after the U.S. FDA accepted the company’s resubmitted Biologics License Application (BLA) for ONS‑5010/LYTENAVA, its bevacizumab-based eye drug for wet AMD, and set a PDUFA review date of December 31, 2025. Here’s what

13 November 2025

Biotech·FDA News·Pharmaceutical Industry·Stock Market

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (NASDAQ: MRSN) is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN

13 November 2025

Biotech News·Mergers & Acquisitions·Pharmaceutical Industry

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and

10 November 2025

Biotech News·Clinical Trials·Investment Updates·Mergers and Acquisitions·Pharmaceutical Industry

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Company Overview & 2025 Developments Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals (pets) and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This

4 November 2025

Biotechnology·Investment Insights·Pharmaceutical Industry·Stock Analysis

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

High-Flying Share Price and Recent Performance 🚀 As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89

3 November 2025

Investing·Market Analysis·Pharmaceutical Industry·Stocks

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening

27 October 2025

Biotechnology·Pharmaceutical Industry·Stock Market

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the

27 October 2025

Biotechnology·Clinical Trials·Mergers & Acquisitions·Pharmaceutical Industry·Stock Market

Pharmaceutical Industry News 27 October 2025 - 29 November 2025